265 related articles for article (PubMed ID: 30811963)
1. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
[TBL] [Abstract][Full Text] [Related]
2. Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.
Collins GT; Gerak LR; Javors MA; France CP
J Pharmacol Exp Ther; 2016 Jan; 356(1):85-95. PubMed ID: 26534942
[TBL] [Abstract][Full Text] [Related]
3. Repeated 7-Day Treatment with the 5-HT
Banks ML; Negus SS
Neuropsychopharmacology; 2017 Apr; 42(5):1082-1092. PubMed ID: 27857126
[TBL] [Abstract][Full Text] [Related]
4. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.
Anastasio NC; Sholler DJ; Fox RG; Stutz SJ; Merritt CR; Bjork JM; Moeller FG; Cunningham KA
Neuropharmacology; 2020 May; 168():108009. PubMed ID: 32145488
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
Gannon BM; Sulima A; Rice KC; Collins GT
J Pharmacol Exp Ther; 2018 Mar; 364(2):359-366. PubMed ID: 29217539
[TBL] [Abstract][Full Text] [Related]
6. Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.
Johns SE; Keyser-Marcus L; Abbate A; Boone E; Van Tassell B; Cunningham KA; Anastasio NC; Poklis JL; Ramey T; Moeller FG
Front Psychiatry; 2021; 12():666945. PubMed ID: 34276440
[No Abstract] [Full Text] [Related]
7. Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166).
Chausmer AL; Smith BJ; Kelly RY; Griffiths RR
Behav Pharmacol; 2003 Mar; 14(2):111-20. PubMed ID: 12658071
[TBL] [Abstract][Full Text] [Related]
8. Effects of lorcaserin (Belviq
Jacobs DS; Barkin CE; Kohut MR; Bergman J; Kohut SJ
Drug Alcohol Depend; 2017 Dec; 181():94-101. PubMed ID: 29040827
[TBL] [Abstract][Full Text] [Related]
9. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys.
Collins GT; France CP
Exp Clin Psychopharmacol; 2018 Oct; 26(5):488-496. PubMed ID: 29952618
[TBL] [Abstract][Full Text] [Related]
10. Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.
Gerak LR; Collins GT; Maguire DR; France CP
Exp Clin Psychopharmacol; 2019 Feb; 27(1):78-86. PubMed ID: 30382731
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
12. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
Higgins GA; Fletcher PJ; Shanahan WR
Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
[TBL] [Abstract][Full Text] [Related]
13. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE
J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655
[TBL] [Abstract][Full Text] [Related]
14. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.
Arout CA; Cooper ZD; Reed SC; Foltin RW; Comer SD; Levin FR; Haney M
Addict Biol; 2021 Jul; 26(4):e12993. PubMed ID: 33389797
[TBL] [Abstract][Full Text] [Related]
15. The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity.
Harvey-Lewis C; Li Z; Higgins GA; Fletcher PJ
Neuropharmacology; 2016 Feb; 101():237-45. PubMed ID: 26427596
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine does not alter cocaine-induced subjective effects or self-administration.
Patel M; Verrico CD; De La Garza R
Pharmacol Biochem Behav; 2019 Oct; 185():172758. PubMed ID: 31430484
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
[TBL] [Abstract][Full Text] [Related]
18. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
[TBL] [Abstract][Full Text] [Related]
20. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
